Jincheng Pharm Reports Progress in Vaping Nicotine Project

On the evening of August 18, Jincheng Pharm released its 2023 interim report, announcing that the company's operating income reached 1.705 billion yuan, a year-on-year decrease of 7.91%; the net profit attributable to shareholders of the listed company was 102 million yuan. In the announcement, it stated that the progress of key projects such as e-cigarette nicotine has been smooth, and they are expected to become important sources of income and profit in the future.

In terms of "key projects," Jincheng Pharmaceuticals mentioned that its subsidiary, Jincheng Pharmaceuticals, has made positive progress in several high-value-added key projects, which are expected to provide support for the company's medium to long-term performance. Among them, the e-cigarette nicotine project, which has attracted much attention, has achieved good production and sales, with sales reaching nearly 17 tons in the first half of the year. 

In July of this year, Jincheng Pharm obtained a newly issued "Tobacco Monopoly Production Enterprise License," which allows the company to expand the production scale of e-cigarette nicotine, obtain new export qualifications, and extend the validity period of the certificate. This is beneficial for the company to legally carry out the production, sales, and export of e-cigarette nicotine. The company stated that it will continue to promote nicotine technology transformation and equipment upgrades, further improve product capacity, and continuously meet the downstream customers' demands.